Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 5, 2018
Event: Entry into a Material Definitive Agreement and divestiture of specific assets.
Key Financial Metrics
Transaction Value: $7.4 million in cash received at closing.
Assets Divested: Inventory, equipment, tangible assets, intellectual property, registrations, approvals, and records related to the Reddick Cholangiogram Catheter and Reddick-Saye Screw.
Counterparty: Specialty Surgical Instrumentation, Inc. (a wholly-owned subsidiary of Symmetry Surgical, Inc.).
Other Financial Data: The filing text does not provide a clear value for overall revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
- Divestiture: The Company sold general surgery products (Reddick Cholangiogram Catheter and Reddick-Saye Screw) to exit that specific product line.
- Cash Inflow: Immediate receipt of $7.4 million upon consummation of the transaction on April 5, 2018.
- Operational Restriction: The Company agreed to a three-year non-compete covenant regarding the sold business.
Outlook, Risks, and Agreements
- Transition Services: A transition services agreement was executed to facilitate the handover of operations.
- Supply Agreement: A long-term balloon supply agreement was established with the buyer.
- Indemnification: Both parties are obligated to indemnify each other for breaches of representations, warranties, covenants, and specified liabilities.
- Disclosure: The Company issued a press release on April 5, 2018, regarding this transaction (Regulation FD Disclosure).
Investor Verification Checklist
- Verify the impact of the $7.4 million cash inflow on the Company's balance sheet in the upcoming Form 10-Q.
- Confirm the revenue contribution of the divested Reddick Cholangiogram Catheter and Reddick-Saye Screw products in prior periods to assess the impact on future top-line growth.
- Review the terms of the long-term balloon supply agreement to ensure it does not create unfavorable pricing or dependency risks.
- Monitor the three-year non-compete period to ensure no inadvertent competitive activities occur.